



EFW

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:

Elizabeth Jaffee *et al.*

Serial No.: 10/618,088

Atty. Docket No: 001107.00363

Filed: July 14, 2003

Group Art Unit: 1632

For: MESOTHELIN VACCINES AND MODEL SYSTEMS

Examiner: TBD

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, V.A. 22313

Dear Sir:


Submitted herewith is one (1) sheet of Form PTO-1449. A copy of each of the non-patent and foreign references listed therein is enclosed. References WO 00/20027 and WO 97/25068 have been previously cited. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By:

  
Sarah A. Kagan  
Registration No. 32,141

Dated: April 25, 2006

Banner & Witcoff, Ltd.  
Customer No. 22907



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/618,088
Filing Date	July 14, 2003
First Named Inventor	Elizabeth Jaffee et al.
Art Unit	1632
Examiner Name	TBD

Attorney Docket Number 001107.00363

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
		US- 2002-019331	02/14/2002	Cheever et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
					T <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Sensi et al., "Intraleisional Selection of T Cell Clonotypes in the Immune Response to Melanoma Antigens Occurring During Vaccination," Journal of Immunotherapy, May 1998, Vol. 21, No. 3, pp. 198-204			
		Berd et al., "Induction of Cell-Mediated Immunity to Autologous Melanoma Cells and Regression of Metastases After Treatment With a Melanoma Cell Vaccine Preceded by Cyclophosphamide," Cancer Research, May 1986, Vol. 46, pp. 2573-2577			
		Hoon et al., "Suppressor Cell Activity in a Randomized Trial of Patients Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine and Low Dosages of Cyclophosphamide," Cancer Research, September 1, 1990, Vol. 50, pp. 5358-5364			
		Fischereider et al., "Immortalization and Characterization of Human Peritoneal Mesothelial Cells," Kidney International, June 1997, Vol. 51, No. 6, pp. 2006-2012			
		Mazurek et al., "Metabolic Cooperation Between Different Oncogenes During Cell Transformation: Interaction Between Activated RAS and HPV-16 E7," Oncogene, October 18, 2001, Vol. 20, No. 47, pp. 6891-6898			

Examiner Signature		Date Considered
--------------------	--	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.